Myostatin (GDF-8) as a key factor linking muscle mass and bone structure

Journal of Musculoskeletal Neuronal Interactions

Volumn 10, Issue 1, 2010, Pages 56-63

  Elkasrawy, Moataz N ^a   Hamrick, M W ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

ActRIIB; Bone density; GDF 8; Hypertrophy; Muscle bone interactions

Indexed keywords

MYOSTATIN;

BONE DENSITY; BONE STRENGTH; BONE STRUCTURE; CALLUS; CELL DIFFERENTIATION; CELL PROLIFERATION; FRACTURE HEALING; JAW; LIMB; MESENCHYMAL STEM CELL; MUSCLE MASS; NONHUMAN; PHENOTYPE; PROTEIN ANALYSIS; REVIEW; SIGNAL TRANSDUCTION; SPINE;

ANIMALS; BONE DENSITY; BONE DEVELOPMENT; BONE DISEASES, METABOLIC; BONE REGENERATION; DISEASE MODELS, ANIMAL; HUMANS; HYPERTROPHY; MESENCHYMAL STEM CELLS; MICE; MUSCLE, SKELETAL; MUSCULOSKELETAL DEVELOPMENT; MYOSTATIN;

EID: 77649198629     PISSN: 11087161     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (54)

1. McPherron AC, Lawler AM, Lee SJ. Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature 1997;387:83-90.
2. Lee SJ. Regulation of muscle mass by myostatin. Annu Rev Cell Dev Biol 2004;20:61-86.
3. Schuelke M, Wagner KR, Stolz LE, Hubner C, Riebel T, Komen W, et al. Myostatin mutation associated with gross muscle hypertrophy in a child. N Engl J Med 2004;350:2682-8.
4. McPherron AC, Lee SJ. Suppression of body fat accumulation in myostatin-deficient mice. J Clin Invest 2002; 109:595-601.
5. Tsuchida K. Activins, myostatin and related TGF-beta family members as novel therapeutic targets for endocrine, metabolic and immune disorders. Curr Drug Targets Immune Endocr Metabol Disord 2004;4:157-66.
6. Allendorph GP, Vale WW, Choe S. Structure of the ternary signaling complex of a TGF-beta superfamily member. Proc Natl Acad Sci USA 2006;103:7643-8.
7. Steelman CA, Recknor JC, Nettleton D, Reecy JM. Transcriptional profiling of myostatin-knockout mice implicates Wnt signaling in postnatal skeletal muscle growth and hypertrophy. Faseb J 2006;20:580-2.
8. Joulia-Ekaza D, Cabello G. The myostatin gene: physiology and pharmacological relevance. Curr Opin Pharmacol 2007;7:310-5.
9. Rauch F, Schoenau E. The developing bone: slave or master of its cells and molecules? Pediatr Res 2001;50:309-14.
10. Frost HM. Muscle, bone, and the Utah paradigm: a 1999 overview. Med Sci Sports Exerc 2000;32:911-7.
11. Frost HM. On our age-related bone loss: insights from a new paradigm. J Bone Miner Res 1997;12:1539-46.
12. Bouvier M, Zimny ML. Effects of mechanical loads on surface morphology of the condylar cartilage of the mandible in rats. Acta Anat (Basel) 1987;129:293-300.
13. Borer KT. Characteristics of growth-inducing exercise. Physiol Behav 1980;24:713-20.
14. Montero A, Okada Y, Tomita M, Ito M, Tsurukami H, Nakamura T, et al. Disruption of the fibroblast growth factor-2 gene results in decreased bone mass and bone formation. J Clin Invest 2000;105:1085-93.
15. Yao Z, Lafage-Proust MH, Plouet J, Bloomfield S, Alexandre C, Vico L. Increase of both angiogenesis and bone mass in response to exercise depends on VEGF. J Bone Miner Res 2004;19:1471-80.
16. Hamrick MW, Pennington C, Webb CN, Isales CM. Resistance to body fat gain in 'double-muscled' mice fed a high-fat diet. Int J Obes (Lond) 2006;30:868-70.
17. Hamrick MW, McPherron AC, Lovejoy CO. Bone mineral content and density in the humerus of adult myostatin-deficient mice. Calcif Tissue Int 2002;71:63-8.
18. Mendias CL, Bakhurin KI, Faulkner JA. Tendons of myostatin-deficient mice are small, brittle, and hypocellular. Proc Natl Acad Sci USA 2008;105:388-93.
19. Hamrick MW, McPherron AC, Lovejoy CO, Hudson J. Femoral morphology and cross-sectional geometry of adult myostatin-deficient mice. Bone 2000;27:343-9.
20. Hamrick MW. Increased bone mineral density in the femora of GDF8 knockout mice. Anat Rec A Discov Mol Cell Evol Biol 2003;272:388-91.
21. Hamrick MW, Samaddar T, Pennington C, McCormick J. Increased muscle mass with myostatin deficiency improves gains in bone strength with exercise. J Bone Miner Res 2006;21:477-83.
22. Hamrick MW, Shi X, Zhang W, Pennington C, Thakore H, Haque M, et al. Loss of myostatin (GDF8) function increases osteogenic differentiation of bone marrow-derived mesenchymal stem cells but the osteogenic effect is ablated with unloading. Bone 2007;40:1544-53.
23. Kellum E, Starr H, Arounleut P, Immel D, Fulzele S, Wenger K, et al. Myostatin (GDF-8) deficiency increases fracture callus size, Sox-5 expression, and callus bone volume. Bone 2009;44:17-23.
24. Cho TJ, Gerstenfeld LC, Einhorn TA. Differential temporal expression of members of the transforming growth factor beta superfamily during murine fracture healing. J Bone Miner Res 2002;17:513-20.
25. Hamrick MW, Pennington C, Byron CD. Bone architecture and disc degeneration in the lumbar spine of mice lacking GDF-8 (myostatin). J Orthop Res 2003;21:1025-32.
26. McPherron AC, Huynh TV, Lee SJ. Redundancy of myostatin and growth/differentiation factor 11 function. BMC Dev Biol 2009;9:24.
27. McPherron AC, Lawler AM, Lee SJ. Regulation of anterior/ posterior patterning of the axial skeleton by growth/differentiation factor 11. Nat Genet 1999;22:260-4.
28. Oh SP, Li E. The signaling pathway mediated by the type IIB activin receptor controls axial patterning and lateral asymmetry in the mouse. Genes Dev 1997;11:1812-26.
29. Nakashima M, Toyono T, Akamine A, Joyner A. Expression of growth/differentiation factor 11, a new member of the BMP/TGFbeta superfamily during mouse embryogenesis. Mech Dev 1999;80:185-9.
30. Gamer LW, Cox KA, Small C, Rosen V. Gdf11 is a negative regulator of chondrogenesis and myogenesis in the developing chick limb. Dev Biol 2001;229407-20.
31. Bouvier M. Effects of age on the ability of the rat temporomandibular joint to respond to changing functional demands. J Dent Res 1988;67:1206-12.
32. Ravosa MJ, Kunwar R, Stock SR, Stack MS. Pushing the limit: masticatory stress and adaptive plasticity in mammalian craniomandibular joints. J Exp Biol 2007; 210(Pt.4):628-41.
33. Byron CD, Borke J, Yu J, Pashley D, Wingard CJ, Hamrick M. Effects of increased muscle mass on mouse sagittal suture morphology and mechanics. Anat Rec A Discov Mol Cell Evol Biol 2004;279:676-84.
34. Vecchione L, Byron C, Cooper GM, Barbano T, Hamrick MW, Sciote JJ, et al. Craniofacial morphology in myostatin-deficient mice. J Dent Res 2007;86:1068-72.
35. Ravosa MJ, Klopp EB, Pinchoff J, Stock SR, Hamrick MW. Plasticity of mandibular biomineralization in myostatin-deficient mice. J Morphol 2007;268:275-82.
36. Ravosa MJ, Lopez EL, Menegaz RA, Stock SR, Stack MS, hamrick MW. Using "mighty mouse" to understand masticatory plasticity: myostatin-deficient mice and musculoskeletal function. Integr Comp Biol 2008;48:345-59.
37. Byron CD, Maness H, Yu JC, Hamrick MW. Enlargement of the temporalis muscle and alterations in the lateral cranial vault. Integr Comp Biol 2008;48:338-44.
38. Nicholson EK, Stock SR, Hamrick MW, Ravosa MJ. Biomineralization and adaptive plasticity of the temporomandibular joint in myostatin knockout mice. Arch Oral Biol 2006;51:37-49.
39. Zhang ZL, He JW, Qin YJ, Hu YQ, Li M, Zhang H, et al. Association between myostatin gene polymorphisms and peak BMD variation in Chinese nuclear families. Osteoporos Int 2008;19:39-47.
40. Mitchell AD, Wall RJ. In vivo evaluation of changes in body composition of transgenic mice expressing the myostatin pro domain using dual energy X-ray absorptiometry. Growth Dev Aging 2007;70:25-37.
41. Guo W, Flanagan J, Jasuja R, Kirkland J, Jiang L, Bhasin S. The effects of myostatin on adipogenic differentiation of human bone marrow-derived mesenchymal stem cells are mediated through cross-communication between Smad3 and Wnt/beta-catenin signaling pathways. J Biol Chem 2008;283:9136-45.
42. Artaza JN, Bhasin S, Magee TR, Reisz-Porszasz S, Shen R, Groome NP, et al. Myostatin inhibits myogenesis and promotes adipogenesis in C3H 10T(1/2) mesenchymal multipotent cells. Endocrinology 2005;146:3547-57.
43. Rebbapragada A, Benchabane H, Wrana JL, Celeste AJ, Attisano L. Myostatin signals through a transforming growth factor beta-like signaling pathway to block adipogenesis. Mol Cell Biol 2003;23:7230-42.
44. Nagamine T, Imamura T, Ishidou Y, Kato M, Murata F, ten Dijke P, et al. Immunohistochemical detection of activin A, follistatin, and activin receptors during fracture healing in the rat. J Orthop Res 1998;16:314-21.
45. Taylor WE, Bhasin S, Artaza J, Byhower F, Azam M, Willard DH, Jr., et al. Myostatin inhibits cell proliferation and protein synthesis in C2C12 muscle cells. Am J Physiol Endocrinol Metab 2001;280:E221-8.
46. Chelh I, Meunier B, Picard B, Reecy MJ, Chevalier C, Hocquette JF, et al. Molecular profiles of Quadriceps muscle in myostatin-null mice reveal PI3K and apoptotic pathways as myostatin targets. BMC Genomics 2009; 10:196.
47. Zhu J, Li Y, Shen W, Qiao C, Ambrosio F, Lavasani M, et al. Relationships between transforming growth factor-beta1, myostatin, and decorin: implications for skeletal muscle fibrosis. J Biol Chem 2007;282:25852-63.
48. Li ZB, Kollias HD, Wagner KR. Myostatin directly regulates skeletal muscle fibrosis. J Biol Chem 2008; 283:19371-8.
49. Eliasson P, Andersson T, Aspenberg P. Myostatin stimulates early tendon healing and responds to mechanical loading. Trans Orthop Res Soc 234. 2009.
50. Bialek P. Mice treated with myostatin/GDF-8 decoy receptor, ActRIIB-Fc, exhibit a tremendous increase in bone mass. Bone 2008;42/S1:S46.
51. Hamrick MW, Arounleut P, Kellum E, Cain M, Immel D, Liang L. Recombinant myostatin (GDF-8) propeptide enhances the repair and regeneration of both muscle and bone in a model of deep penetrant musculoskeletal injury. J Trauma; in press.
52. Hamrick M, Arounleut P, Kellum E, Cain M, Elkasrawy M, F S, et al. Effects of recombinant myostatin propeptide on fracture repair in a fibula osteotomy model. Trans Orthop Res Soc 0936. 2009.
53. Zimmers TA, Davies MV, Koniaris LG, Haynes P, Esquela AF, Tomkinson KN, et al. Induction of cachexia in mice by systemically administered myostatin. Science 2002;296:1486-8.
54. Reisz-Porszasz S, Bhasin S, Artaza JN, Shen R, Sinha-Hikim I, Hogue A, et al. Lower skeletal muscle mass in male transgenic mice with muscle-specific overexpression of myostatin. Am J Physiol Endocrinol Metab 2003;285:E876-88.